Xtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200-Day Moving Average – What’s Next?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.00 and traded as high as $0.47. Xtant Medical shares last traded at $0.46, with a volume of 8,616 shares.

Xtant Medical Stock Performance

The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The stock has a market cap of $63.25 million, a price-to-earnings ratio of -3.50 and a beta of 0.35. The firm’s fifty day moving average price is $0.53.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC lifted its stake in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 15.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 798,033 shares of the medical device company’s stock after buying an additional 103,825 shares during the period. Renaissance Technologies LLC owned approximately 0.57% of Xtant Medical worth $354,000 at the end of the most recent quarter. Institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.